| abstract |
This paper discloses new benzenesulfonyl asymmetric ureas corresponding to general formulas (I) to (IV) and pharmaceutically acceptable salts thereof. The structure and substituents of the urea are described in detail in this specification. Procedures for the synthesis of this compound are disclosed herein. The compound acts on the ghrelin receptor, in particular the compound has inverse agonist activity; the compound is used for the prevention and/or treatment of pathophysiologically mediated diseases by the ghrelin receptor, such as, for example, obesity, Diabetes and substance abuse. Also disclosed herein are pharmaceutical compositions comprising a compound as defined herein and a pharmaceutically acceptable carrier or vehicle. |